Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-11-16 Investor Presentation
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Investor Presentation Classification · 1% confidence The document is a press release dated November 16, 2016, announcing that ABIVAX will present clinical data for its drug candidate ABX464 at the 'Strategies for an HIV Cure Meeting 2016'. It details preliminary results, quotes management regarding ongoing and future studies, and provides company background. This type of announcement, focusing on scientific data presentation at a conference and providing updates on clinical progress, is characteristic of an Investor Presentation (IP) or a general press release related to investor/scientific updates. Since it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a formal report (AR, IR), and it serves to inform investors about scientific milestones and upcoming presentations, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. Given the options, 'IP' covers detailed scientific/pipeline updates intended for investors. It is not a Call Transcript (CT), nor is it a formal Earnings Release (ER) which focuses on financial performance metrics. It is an announcement about data being presented, which aligns closely with the content shared in an Investor Presentation.
2016-11-16 French
ABIVAX prasentiert auf bevorstehenden Investorenkonferenzen
Report Publication Announcement Classification · 1% confidence The document is a press release dated November 15, 2016, announcing that ABIVAX management representatives will be presenting and holding investor meetings at upcoming investor conferences (Deutschen Eigenkapitalforum and 28th Annual Piper Jaffray Healthcare Conference). This type of announcement, detailing management's schedule for engaging with investors at external events, aligns best with the Investor Presentation (IP) category, as it is directly related to investor outreach and presentation schedules, even though it is not the presentation itself. However, given the options, the content is a direct announcement about investor engagement schedules, which is a key component of investor relations activities often associated with Investor Presentations (IP) or general Investor Relations materials. Since it is an announcement about future presentations/meetings rather than the presentation itself, and it is not a standard regulatory filing like 10-K or ER, 'Investor Presentation' (IP) is the most fitting category describing the *purpose* of the communication, although 'Regulatory Filings' (RNS) could be a fallback if the intent was purely dissemination. Given the specific mention of presentations and investor meetings, IP is stronger than RNS. The document length is short (3940 chars), but it is not announcing the publication of a major report, but rather an event schedule.
2016-11-15 German
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Investor Presentation Classification · 1% confidence The document is a press release dated November 15, 2016, announcing that members of ABIVAX management have been invited to present at upcoming investor conferences (German Equity Forum and Piper Jaffray Annual Health Conference). It details the dates, times, and locations of these presentations and provides contact information for scheduling meetings with management during these events. This content directly relates to investor relations activities, specifically scheduling management appearances at external industry/investor events, which aligns best with the Investor Presentation (IP) category if it were the presentation itself, or more generally, an announcement about investor engagement. Since it is an announcement about management presenting at investor conferences, it falls under the scope of investor communications. Given the options, 'Investor Presentation (IP)' is the closest fit for management presenting strategy/financials, although this is an announcement *about* presentations rather than the presentation slides themselves. However, since there is no specific code for 'Investor Conference Announcement', and the content is entirely focused on management's engagement with investors at conferences, 'IP' is the most appropriate classification among the choices, as these events typically involve management presentations or discussions about the company's investment case.
2016-11-15 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Investor Presentation Classification · 1% confidence The document is a press release dated November 15th, 2016, announcing that ABIVAX senior management will be presenting and hosting meetings at two upcoming investor conferences: the German Equity Forum and the 28th Annual Piper Jaffray Healthcare Conference. This type of announcement, detailing management's schedule for engaging with investors at external industry events, is best classified as an Investor Presentation (IP) or a general announcement related to investor relations activities. Since 'Investor Presentation' (IP) is defined as a detailed presentation focusing on financials, strategy, and market position, and this document is an announcement *about* management's participation in investor events (which often includes presenting company materials), IP is the most fitting category among the specific options, as it relates directly to investor engagement and presentation schedules. It is not a formal regulatory filing like 10-K or ER, nor is it a general regulatory announcement (RNS) or a report publication announcement (RPA) in the strict sense, as it is announcing future events, not the release of a specific attached report.
2016-11-15 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code (L. 233-8 II) and AMF regulations (Article 223-16), providing a table detailing the number of shares and voting rights as of a specific date (31/10/2016). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing, often related to changes in major shareholdings or capital structure transparency. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a specific notification about the total voting power. This fits best under Major Shareholding Notification (MRQ) as it relates to the calculation basis for crossing ownership thresholds, or potentially Regulatory Filings (RNS) if MRQ is too specific for this exact format. Given the content is a direct disclosure of the total voting rights calculation basis required by regulators, it strongly aligns with the intent of Major Shareholding Notification (MRQ) which covers changes in significant ownership levels, as the voting rights calculation is central to determining those levels. However, since the definition for MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)', and this document provides the *current total* for threshold calculation, it is a very close fit. If it were purely a notification of a threshold being crossed, MRQ would be perfect. Since it is the underlying data for that, MRQ is the most relevant specific category related to share ownership reporting.
2016-11-08 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated October 28, 2016, announcing that the CEO of ABIVAX will attend the Jefferies 2016 London Healthcare Conference. It details the conference, the company's lead product (ABX464), and provides contact information. This type of announcement, which informs investors about management participation in industry events, does not fit the specific definitions for financial reports (10-K, IR, ER), corporate actions (CAP, DIV, SHA), or governance filings (DEF 14A, CGR). It is a general communication to the investment community regarding corporate visibility and pipeline updates, which is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Since it is an announcement *about* attending a conference, RNS is the most appropriate general category for non-standard, informational corporate news releases.
2016-10-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.